Sampat Ingale
About
Sampat Ingale is from Greater Boston. Sampat is currently Senior Director of Peptide and Protein Chemistry at Biohaven, located in Cambridge, MA. Sampat also works as Director of Peptide Chemistry at Biohaven, a job Sampat has held since Sep 2023. In Sampat's previous role as a Director of Chemistry at Flagship Pioneering, Sampat worked in Cambridge, Massachusetts, United States until May 2023. Prior to joining Flagship Pioneering, Sampat was a Principal Scientist- Bioconjugation and Peptide Chemsitry at Merck and held the position of Principal Scientist- Bioconjugation and Peptide Chemsitry at Cambridge, Massachusetts. Prior to that, Sampat was a Associate Principal Scientist-Bioconjugation and Peptide Chemistry at Merck from Jun 2017 to Nov 2021. Sampat started working as Senior Research Scientist - Protein and Peptide Chemistry at Novo Nordisk in Seattle, Washington in Dec 2016. From Oct 2015 to Dec 2016, Sampat was Scientist at Sorrento Therapeutics, Inc., based in Greater San Diego Area. Prior to that, Sampat was a Research Associate at The Scripps Research Institute, based in La Jolla, CA from Mar 2013 to Oct 2015. Sampat started working as Senior Manager-Global Discovery at Nycomed Pharma Private Limited in Andheri, Mumbai, India in Apr 2011.
You can find Sampat Ingale's email on finalScout.com. FinalScout is a popular professional database with more than 500 million business professionals and over 200 million company profiles.
Sampat Ingale's current jobs
Sampat Ingale's past jobs
- Explored strategies for lipid nanoparticle decoration with various ligand for active targeting of immune cells and extrahepatic delivery
- Developed site-specific conjugation method to improve ADC design by glycoengineering Fc glycan - Peptide mRNA display platform - Presentation of antigens (Carrier protein, Lipid Nanoparticle, Virus-like Particle (VLPs) - Synthetic peptide based antigen design and evaluation
Bioconjugation capability build at Cambridge site – Led and assembled group (recruit, capital investment) – Synthesize, purify and characterize diverse therapeutic modalities including peptides, macrocyclic peptides, peptide-peptide bicyclic molecules, ADCs, peptide/glycan-carrier protein conjugates - Established workflow for synthesis, analysis and purification of small and large molecules (HIC, IEX, RP-HPLC, LC-MS, SEC-MALS, CE-SDS, NMR, AKTA) – Developed processes for enzymatic (sortase) and chemical (engineered cysteine) for site-specific conjugation - Characterization and design of drug-linker payloads for new ADCs development
• Structure activity relationships for peptides targeting obesity
- Antibody Oligonucleotide Conjugation (random lysine, cys) - Purification of conjugates (Protein A, HIC, Size exclusion)
• Facilitated various global discovery projects to achieve decision gate milestones by monitoring and allocating resources for multi-step, small molecule synthesis • Supervised centralized purification and analysis group: compound purification (HPLC), characterization and identification (LC-MS/NMR/GC), method development and modernized incoming and outgoing sample flow
1) Ingale, S.; Dawson, P.E. On Resin Side-Chain Cyclization of Complex Peptides Using CuAAC. Org. Lett. 2011, 16, 716-722 2) Ingale, S.; Gach, J.S.; Zwick, M.B. Dawson, P.E. Synthesis and Analysis of the Membrane Proximal External Region (MPER) Epitopes of HIV-1. J. Pept. Sci. 2010, 16, 716-722
Development of oral care formulations